YMC Co., Ltd.
Comment: Reference 1 is a routine database listing and References 2, 3, 4, and 5 are not independent of the subject. Also requires a complete rewrite per WP:NEWLLM. 🌀Hurricane Wind and Fire, why did you decline my draft? (talk) (contribs)🔥 18:24, 20 July 2026 (UTC)
 | This article appears to have been generated by a large language model (such as ChatGPT) without having been rigorously scrutinized for verifiability, neutrality, original research, and copyright compliance. It may include misleading or inaccurate claims and fake references that sound plausible. (July 2026) (Learn how and when to remove this template message) |
YMC Co., Ltd. (株式会社ワイエムシィ) is a Japanese manufacturer specializing in separation science, high-performance liquid chromatography (HPLC) equipment, and downstream bioprocess purification hardware.[1] Headquartered in Kyoto, Japan, the company produces chemical stationary phases, packed columns, and automation systems used by the global pharmaceutical and biotechnology industries to isolate and purify compounds.[2]
History and expansion
The company was founded on January 28, 1980, by Ryuji Yamamura as the Yamamura Chemical Research Institute in Yawata, Kyoto, before transferring its primary headquarters to Kyoto City.[3] The firm initially developed and commercialized silica-gel packing materials under the brand "YMC*GEL" for high-pressure analytical systems.[3]
To transition from analytical laboratory scale supplies to industrial-scale bioprocessing, the company pursued international mergers and acquisitions:
- LEWA-Nikkiso Bioprocess: YMC acquired the pharmaceutical system integration business from LEWA-Nikkiso America, establishing its dedicated YMC Process Technologies (YMPT) manufacturing center in Devens, Massachusetts.[4]
- ChromaCon AG: In 2019, YMC fully acquired Zurich-based chromatography firm ChromaCon AG, absorbing its complete portfolio of patents related to continuous multi-column chromatography layouts.[4]
Technology and regulatory adoption
YMC specializes in the production of bio-inert hybrid silica stationary phases (such as the YMC-Triart line) utilized in high-pressure environments to limit non-specific adsorption of biological samples.[4]
In 2020, the United States Food and Drug Administration (FDA) selected YMC’s Contichrom CUBE twin-column continuous chromatography platform for internal laboratory evaluation to assist in standardizing continuous purification metrics for complex synthetic peptides and oligonucleotides.[5]
References
- ↑ "YMC Co., Ltd. Company Profile". The Worldfolio. Retrieved July 17, 2026.
- ↑ "Corporate Outline". YMC Co., Ltd. Official. Retrieved July 17, 2026.
- ↑ 3.0 3.1 "Corporate History". YMC Co., Ltd. Official. Retrieved July 17, 2026.
- ↑ 4.0 4.1 4.2 Gach, Gary (August 1, 2019). "YMC Strengthens Continuous Expertise via Acquisitions". Genetic Engineering & Biotechnology News. Retrieved July 17, 2026.
- ↑ "FDA Selects YMC Twin-Column Continuous Chromatography System for Evaluation". ChromaCon News Portal. Retrieved July 17, 2026.
External links
 | This article about a Japanese corporation– or company–related topic is a stub. You can help EverybodyWiki by expanding it. |
Template:Chemistry-equipment-stub
This article "YMC Co., Ltd." is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:YMC Co., Ltd.. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
